Table 4 Misdiagnosis of benign GCTB
From: Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Patient no.a (age range) | Cohort | Site at enrollment | Malignant histology | Malignancy present prior to denosumab? | Malignancy outcome |
|---|---|---|---|---|---|
15 (20–29 y) | Primary resectable | Distal femur | Giant cell-rich osteosarcoma | Likelyb | Amputation; deceased 12 mo after malignancy diagnosis |
16 (70–79 y) | Recurrent unresectable | Pubic ramus | Pleomorphic rhabdomyosarcoma | Likelyb | Deceased 6 mo after malignancy diagnosis |
17 (40–49 y) | Recurrent unresectable | Lung | Undifferentiated spindle cell sarcoma | Yes | Deceased 4 mo after malignancy diagnosis |
18 (20–29 y) | Recurrent unresectable | Femur | Osteogenic sarcoma (present pre-enrollment) | Yes | Chemotherapy and resection of tumor; alive at last follow-up |
19 (10–19 y) | Recurrent unresectable | Lung and cuneiform bones of foot | Phosphaturic mesenchymal tumor of mixed connective tissue type | Yes | Alive at last follow-up with progressive disease |
20 (30–39 y) | Recurrent resectable | Humerus | Undifferentiated spindle cell sarcoma | Yes | Alive at last follow-up |